Evaluating the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) We expect to enroll 6 patients in this part of the project.
|Effective start/end date||9/18/15 → 8/31/19|
- University of Texas Southwestern Medical School (GMO-170910//5U01DK058369-19)
- National Institute of Diabetes, Digestive and Kidney Diseases (GMO-170910//5U01DK058369-19)
Acute Liver Failure
Wounds and Injuries